Aikido pharma inc. (SPEX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenues

9

28

1,236

877

33

10

27

20

0

14

Operating costs and expenses
Cost of revenues

-

-

-

-

-

-

3

0

-

-

Amortization of patent portfolio

-

1,405

1,373

2,135

6,317

9,831

267

0

-

-

Rent

-

-

92

84

88

864

134

164

-

-

Depreciation expense

-

-

3

-

-

-

24

64

-

-

General and administrative

3,172

3,324

493

253

534

1,696

1,010

595

2,548

3,181

Compensation and related expenses (including stock-based compensation)

-

-

2,059

1,950

1,724

13,710

9,783

1,048

-

-

Research and development

2,522

-

-

-

-

-

10

0

1,645

4,846

Professional fees

-

-

1,038

2,293

2,780

4,520

4,143

1,621

-

-

Impairment of intangible assets

-

-

-

2,713

40,600

0

-

-

-

-

Impairment of intangible assets

-

2,173

-

-

-

-

-

-

-

-

Total operating expenses

5,694

6,902

5,058

9,428

52,043

30,621

15,374

3,492

4,193

8,027

Loss from operations

-5,685

-6,874

-3,822

-8,551

-52,010

-30,611

-15,347

-3,472

-4,193

-8,012

Other expenses
Other income (expenses), net

14

-333

291

-182

276

31

0

-

-

-

Change in fair value of investment

1,406

8,194

345

0

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

4

-

-

Loss on issuance of warrants

-

-

-

-

-

-

-

622

4

-

Change in fair value of warrant liabilities

-82

-740

120

-2,257

-269

-48

2,618

-1,202

-

-

Total other expenses

1,502

8,601

516

2,075

545

79

-2,618

584

-

-

Unrealized (loss) gain on the change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-3,716

-

Interest income

-

-

-

-

-

-

-

-

3

6

Other income

-

-

-

-

-

-

-

-

51

135

Gain on settlement of obligations

-

-

-

-

-

-

-

-

-845

-

(Loss) income from continuing operations before taxes

-

-

-

-

-

-

-

-

417

-7,870

Income tax expense

-

-

-

-

-

-

-

-

14

-

Loss from continuing operations

-

-

-

-

-

-

-

-2,888

403

-

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-7,737

Loss from discontinued operations before taxes

-

-

-

-

-

-

-

-

-383

1

Income tax expense

-

-

-

-

-

-

-

-

0

-133

Income tax expense

-

-

-

-

-

-

-

-

-

0

Loss from discontinued operations

-

-

-

-

-

-

-

-969

-383

1

Net loss

-4,183

1,727

-3,306

-6,476

-51,465

-30,532

-17,965

-3,857

19

-

Deemed capital contribution on extinguishment of preferred stock

-

-

-

-31,480

323

0

-

-

-

-

Deemed capital contribution on extinguishment of preferred stock

-

-

-

-

-9,485

0

-

-

-

-

Net (loss) income attributable to common stockholders

-

-

-

25,004

-42,303

-30,532

-

-

-

-7,736

Net loss per share, basic and diluted
Continuing operations

-

-

-

-

-

-

-

-10.54

-

-85.68

Discontinued operations

-

-

-

-

-

-

-

-3.54

-

0.01

Basic and Diluted

-

-

-

-

-

-29.41

-13.64

-14.08

-

-85.67

Basic (in dollars per share)

-

-

-

6.76

-

-

-

-

3.07

-

Discontinued operations

-

-

-

-

-

-

-

-

-2.92

-

Basic

-1.67

0.91

-0.60

-

-24.98

-

-

-

0.15

-

Diluted (in dollars per share)

-

-

-

6.51

-

-

-

-

-2.37

-

Discontinued operations

-

-

-

-

-

-

-

-

-2.77

-

Diluted

-1.67

0.91

-0.60

-

-24.98

-

-

-

-5.14

-

Weighted average number of shares outstanding, basic and diluted
Basic and Diluted

-

-

-

-

-

1,038

1,317

0

-

90

Basic

2,511

1,896

5,538

3,700

1,693

-

-

-

131

-

Diluted

2,511

1,896

5,538

3,838

1,693

-

-

-

138

-